Coronavirus (COVID-19) Update: Daily Roundup April 3, 2020

Coronavirus (COVID-19) Update: Daily Roundup April 3, 2020

The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The FDA announced that it is leading an effort, working collaboratively with government, industry and academic partners, to develop and implement a protocol that will provide convalescent plasma to patients in need across the country who may not have access to institutions with clinical trials in place.  Convalescent plasma has the potential to lessen the severity or shorten the length of illness caused by COVID-19. This collaboration, involving BARDA, the American Red Cross and the Mayo Clinic, will allow for a simplified process for health care providers that will help ensure patient safety while allowing for the collection of ...

Read Mo

Coronavirus (COVID-19) Update: FDA Coordinates National Effort to Develop Blood-Related Therapies for COVID-19

https://www.theladders.com/career-advice/new-research-shows-covid-19-is-even-more-deadly-for-people-with-this-condition?ltm=KlPi2G2kwmyBVKYp%2B1Vf0fcNLBepVZEJxMVtvgS0orMSMoYFR7UEJrBuED4sGARB&subscriber_type=member&utm_swu=6280&utm_campaign=daily-newsletter&utm_medium=email&utm_term=dnl-4-3-20-coverwallet&utm_source=member&utm_content=dnl-4-3-20-coverwallet

Coronavirus (COVID-19) Update: FDA Coordinates National Effort to Develop Blood-Related Therapies for COVID-19

The U.S. Food and Drug Administration continues to play a critical role in accelerating medical countermeasures to treat and prevent COVID-19. As part of the response to this pandemic, the agency is taking the lead on a national effort to facilitate the development of, and access to, two investigational therapies derived from human blood. These are called convalescent plasma and hyperimmune globulin and are antibody-rich blood products made from blood donated by people who have recovered from the virus. The products can be administered to individuals diagnosed with COVID-19. There are some limited data to ...

Read Mor

The White House is pushing FDA to clear Fujifilm's Avigan for COVID-19. Should the agency obey?

Wednesday, April 1, 2020

Fujifilm ramps up production of flu drug Avigan as possible COVID-19 treatment

Monday, March 30, 2020

Abbott to ship portable, 5-minute coronavirus tests nationwide Saturday, March 28, 2020

Abbott to ship portable, 5-minute coronavirus tests nationwide

Saturday, March 28, 2020

Experts float Roche stroke drug Activase as potential COVID-19 therapy

Friday, March 27, 2020

As the COVID-19 pandemic swells, experts around the globe are working to determine 

Gilead CEO says coronavirus hopeful remdesivir will be 'affordable,' but it could still rake in revenue

Monday, March 30, 2020

Will Gilead Sciences make a fortune out of remdesivir if the antiviral proves itself against the novel coronavirus?

The number of confirmed coronavirus cases topped 1 million globally, almost a quarter of them in the U.S. Suddenly, Asian governments that appeared to be bringing the coronavirus under control are imposing tighter social restrictions as infections — many from overseas — continue to rise. LOS ANGELES TIMES

Coronavirus (COVID-19) Update: FDA Continues to Accelerate Development of Novel Therapies for COVID-19

As part of the Trump Administration’s all-hands-on-deck approach across public, academic and private sectors to combat the COVID-19 pandemic, the U.S. Food and Drug Administration stood up a new program to expedite the development of potentially safe and effective life-saving treatments. The program, known as the Coronavirus Treatment Acceleration Program (CTAP), is using every tool at the agency’s disposal to bring new therapies to sick patients as quickly as possible, while at the same time supporting research to further evaluate whether these medical countermeasures are safe and effective for treating patients infected with this novel virus. “The FDA is announcing a new, comprehensive public-private approach to bring coronavirus treatments to market as fast as possible,” said HHS Secretary Alex Azar. “As part of this new program, the FDA is cutting red tape, redeploying staff and working day and night to review requests from companies, scientists and doctors who are working toward therapies. We are grateful to...

Read More

Utah pharmacy board urges slow steps on using malaria ...

www.sltrib.com › news › 2020/03/24 › utah-pharmacy-board-urges

7 days ago - ... patients, supplying a compounded formulation with hydroxychloroquine. ... The state of Utah wants to slow down panic buying of two drugs that some health ..